Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks [Antiviral Agents]

In Studies 1489 and 1490, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC), or DTG+F/TAF treatment achieved high rates of virologic suppression in HIV-1 treatment-naïve participants through Week 48. Pre-existing primary drug resistance was present at 1.3% INSTI resistance (-R), 2.7% NRTI-R, 14.1% NNRTI-R, and 3.5% PI-R in the 1274 participants from these studies. These mutations did not affect treatment outcomes. Resistance analyses in 13 virologic failures found no emergent resistance to study drugs.

https://ift.tt/2NxrHyI